U.S. flag

An official website of the United States government

Filters

reset all
See more specimen types...
See more states

Other countries

See more countries

Results: 1 to 20 of 69

Tests names and labsConditionsGenes, analytes, and microbesMethods

Maturity-onset Diabetes of the Young Panel

Genetic Diagnostic Laboratory University of Pennsylvania School of Medicine
United States
1415
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

MODY Panel

Genetic Services Laboratory University of Chicago
United States
1015
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

MODY 2 testing (GCK)

Genetic Services Laboratory University of Chicago
United States
11
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Maturity onset diabetes of the young type 2 (GCK gene)

Molecular Genetics and Cytogenetics, Clinical Laboratory Service RED DE SALUD UC CHRISTUS
Chile
11
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Maturity-onset diabetes of the young MODY

Health in Code
Spain
123
  • C Sequence analysis of the entire coding region

GCK

Department of Clinical Genetics Odense University Hospital
Denmark
21
  • D Deletion/duplication analysis
  • E Sequence analysis of select exons
  • C Sequence analysis of the entire coding region

GCK - NGS including CNV analysis

Centogene AG - the Rare Disease Company
Germany
41
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

CentoNeuro Panel

Centogene AG - the Rare Disease Company
Germany
18861858
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Intellectual Disability Panel

Centogene AG - the Rare Disease Company
Germany
777770
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

CentoIEM Panel

Centogene AG - the Rare Disease Company
Germany
669688
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Diabetes and Obesity Panel

Centogene AG - the Rare Disease Company
Germany
247262
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

CentoICU Panel

Centogene AG - the Rare Disease Company
Germany
829848
  • C Sequence analysis of the entire coding region

Invitae Hypoglycemia Panel

Invitae
United States
173119
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

MODY and Neonatal Diabetes Panel, Sequencing

ARUP Laboratories, Molecular Genetics and Genomics ARUP Laboratories
United States
1723
  • C Sequence analysis of the entire coding region

Invitae Monogenic Diabetes Panel

Invitae
United States
5928
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Monogenic Diabetes Panel

PreventionGenetics, part of Exact Sciences
United States
10154
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Hypoglycemia Panel - Expanded

PreventionGenetics, part of Exact Sciences
United States
131115
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

MODY, type II, 125851, Autosomal dominant; MODY2 (MODY) (GCK gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Maturity-Onset Diabetes of the Young (MODY) Panel

Ambry Genetics
United States
145
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Maturity Onset Diabetes of the Young (MODY) Panel

PreventionGenetics, part of Exact Sciences
United States
2018
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Results: 1 to 20 of 69

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.